My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Johnson & Johnson (NY:JNJ)

210.01 +3.47 (+1.68%)

Official Closing Price Updated: 7:00 PM EST, Dec 11, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

2 Unstoppable Dividend Stocks to Buy Now With $500 ↗

November 23, 2024

Via The Motley Fool

2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade ↗

November 23, 2024

Via The Motley Fool

Topics Stocks

Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity ↗

November 21, 2024

Via Benzinga

Price Over Earnings Overview: Johnson & Johnson ↗

November 21, 2024

Via Benzinga

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

November 16, 2024

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

Via MarketBeat

This Is What Whales Are Betting On Johnson & Johnson ↗

November 15, 2024

Via Benzinga

Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry ↗

November 07, 2024

Via Benzinga

Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry ↗

October 24, 2024

Via Benzinga

Peering Into Johnson & Johnson's Recent Short Interest ↗

October 22, 2024

Via Benzinga

This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 15, 2024

Via Benzinga

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower ↗

November 14, 2024

Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks.

Via Benzinga

Topics Government

Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology ↗

November 14, 2024

CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage...

Via Talk Markets

Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗

November 14, 2024

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

Via The Motley Fool

Topics ETFs Stocks

Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs ↗

November 13, 2024

Johnson & Johnson sues the U.S. government agency over a 340B Drug Pricing Program dispute, arguing the program's misuse.

Via Benzinga

Topics Lawsuit

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever ↗

November 08, 2024

You'll also like these stocks for their track record of earnings growth.

Via The Motley Fool

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields ↗

November 06, 2024

Via Benzinga

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

November 06, 2024

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

Via MarketBeat

Topics Initial Public Offering

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

November 04, 2024

Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges

From Inovalon Holdings, Inc.

Via GlobeNewswire

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises ↗

October 28, 2024

Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support.

Via Benzinga

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease ↗

October 28, 2024

Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.

Via Benzinga

3 Dividend Growth Stocks You Can Buy and Hold Forever ↗

October 26, 2024

These healthcare stocks have fantastic dividend track records.

Via The Motley Fool

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas ↗

October 25, 2024

Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the SPECTREM Phase 3b study, surpassing placebo.

Via Benzinga

Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government ↗

October 24, 2024

In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left.

Via The Motley Fool

3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime ↗

October 23, 2024

These three Vanguard ETFs are worth considering for the long term.

Via The Motley Fool

Topics ETFs

This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock ↗

October 23, 2024

Fewer contenders means fewer constraints on expanding market share.

Via The Motley Fool

Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability ↗

October 22, 2024

The DOJ's U.S. Trustee Program seeks to dismiss Johnson & Johnson's third attempt to settle 60,000 talc lawsuits via bankruptcy, arguing the filing is a bad-faith strategy to avoid liability.

Via Benzinga

Topics Bankruptcy Lawsuit

Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises ↗

October 22, 2024

The activist investor says Pfizer has underperformed its peers and the broader market since 2019.

Via Investor's Business Daily

What's Going On With Kenvue Stock Monday? ↗

October 21, 2024

Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company.

Via Benzinga

Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies ↗

October 21, 2024

Elf Beauty appeared to rally along with KVUE on Monday.

Via Investor's Business Daily

Topics Stocks

Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump ↗

October 21, 2024

Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.

Via Talk Markets

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.